Neuroinflammation: a potential therapeutic target
- 27 September 2005
- journal article
- review article
- Published by Taylor & Francis in Emerging Therapeutic Targets
- Vol. 9 (5) , 887-900
- https://doi.org/10.1517/14728222.9.5.887
Abstract
The increased appreciation of the importance of glial cell-propagated inflammation (termed ‘neuroinflammation’) in the progression of pathophysiology for diverse neurodegenerative diseases, has heightened interest in the rapid discovery of neuroinflammation-targeted therapeutics. Efforts include searches among existing drugs approved for other uses, as well as development of novel synthetic compounds that selectively downregulate neuroinflammatory responses. The use of existing drugs to target neuroinflammation has largely met with failure due to lack of efficacy or untoward side effects. However, the de novo development of new classes of therapeutics based on targeting selective aspects of glia activation pathways and glia-mediated pathophysiologies, versus targeting pathways of quantitative importance in non-CNS inflammatory responses, is yielding promising results in preclinical animal models. The authors briefly review selected clinical and preclinical data that reflect the prevailing approaches targe...Keywords
This publication has 88 references indexed in Scilit:
- Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trialsAnnals of Oncology, 2005
- NSAID and Antioxidant Prevention of Alzheimer's Disease: Lessons from In Vitro and Animal ModelsAnnals of the New York Academy of Sciences, 2004
- The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune diseaseNature, 2002
- Atypical inflammation in the central nervous system in prion diseaseCurrent Opinion in Neurology, 2002
- Double placebo design in a prevention trial for Alzheimer's diseaseControlled Clinical Trials, 2002
- Clinical Pharmacokinetics and Pharmacodynamics of Cholinesterase InhibitorsClinical Pharmacokinetics, 2002
- Interleukin-1, neuroinflammation, and Alzheimer's diseaseNeurobiology of Aging, 2001
- Hepatotoxicity with ThiazolidinedionesDrug Safety, 2001
- Brief Communication Inhibitory effects of indomethacin on interleukin-1 and nitric oxide production in rat microglia in vitroInternational Journal of Immunopharmacology, 1999
- A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymesTrends in Pharmacological Sciences, 1997